These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4988185)

  • 21. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
    Brandler S; Tangy F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RECENT ADVANCES IN MEASLES VIROLOGY.
    ARAKAWA S
    Ergeb Mikrobiol Immunitatsforsch Exp Ther; 1964; 38():1-38. PubMed ID: 14269508
    [No Abstract]   [Full Text] [Related]  

  • 23. Obtaining of measles virus haemagglutinin from strain L-16 grown in primary cell cultures.
    Dorofeyeva LV
    Acta Virol; 1975 Nov; 19(6):497. PubMed ID: 1998
    [No Abstract]   [Full Text] [Related]  

  • 24. [Seroconversion following vaccination with a new measles vaccine strain].
    Just M; Wegmann A
    Ther Umsch; 1983 Mar; 40(3):261-3. PubMed ID: 6857567
    [No Abstract]   [Full Text] [Related]  

  • 25. The lyophilization of measles virus.
    Mares I; Kittnar E; Srbová H; Casný J
    J Hyg Epidemiol Microbiol Immunol; 1969; 13(3):279-87. PubMed ID: 5387794
    [No Abstract]   [Full Text] [Related]  

  • 26. [Control over the postvaccinal measles immunity status using the indirect hemagglutination test with lyophilized diagnostic agents].
    Sokhin AA; Sliuar' LI; Smorodinova IP; Rodomskaia FS; Makarova EN
    Tr Inst Im Pastera; 1981; 56():121-3. PubMed ID: 7187542
    [No Abstract]   [Full Text] [Related]  

  • 27. Studies on further attenuated live measles vaccine. II. Correlation between the titer of the vaccine, the antibody response and clinical reactions.
    Ueda S; Takahashi M; Minekawa Y; Ogino T; Suzuki N
    Biken J; 1970 Jun; 13(2):117-20. PubMed ID: 5528345
    [No Abstract]   [Full Text] [Related]  

  • 28. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
    Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
    Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines produced in diploid cell lines.
    Ikić D
    Natl Cancer Inst Monogr; 1968 Dec; 29():485-93. PubMed ID: 4976866
    [No Abstract]   [Full Text] [Related]  

  • 30. Atypical measles following immunization with killed measles vaccine.
    McLean DM; Kettyls GD; Hingston J; Moore PS; Paris RP; Rigg JM
    Can Med Assoc J; 1970 Oct; 103(7):743-4. PubMed ID: 5506110
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans.
    Etchart N; Hennino A; Friede M; Dahel K; Dupouy M; Goujon-Henry C; Nicolas JF; Kaiserlian D
    Vaccine; 2007 Sep; 25(39-40):6891-9. PubMed ID: 17764789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic.
    Guerbois M; Moris A; Combredet C; Najburg V; Ruffié C; Février M; Cayet N; Brandler S; Schwartz O; Tangy F
    Virology; 2009 May; 388(1):191-203. PubMed ID: 19345390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dynamics of the serologic response of children vaccinated with live AMN USSR measles vaccine prepared from the ESzCz strain].
    Sinjak KM; Czumakow MP; Rodin WI; Czudnaja LM; Sziechtier AB; Winograd IA; Urin AI; Glinskaja LA; Szwiec LT; Knjaziewa II; Niemiec ZA
    Przegl Epidemiol; 1970; 24(1):15-20. PubMed ID: 5431385
    [No Abstract]   [Full Text] [Related]  

  • 34. Measles vaccine in the People's Republic of China.
    Xiang JZ; Chen ZH
    Rev Infect Dis; 1983; 5(3):506-10. PubMed ID: 6879006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [History of purification, attenuation and testing a measles vaccine made from the strain "Leningrad-16" (L-16)].
    Smorodintsev AA; Taros LIu
    Tr Inst Im Pastera; 1992; 67():86-95. PubMed ID: 8539772
    [No Abstract]   [Full Text] [Related]  

  • 36. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.
    Polack FP; Hoffman SJ; Crujeiras G; Griffin DE
    Nat Med; 2003 Sep; 9(9):1209-13. PubMed ID: 12925847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory methods for assessing vaccine potency retained in aerosol outputs from nebulizers: application to World Health Organization measles aerosol project.
    Cohen BJ; Parry RP; Andrews N; Bennett AM; Dennis JH
    Vaccine; 2008 Jun; 26(27-28):3534-9. PubMed ID: 18490082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA; Harry TO
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selected immunological reactions to measles virus in immunosuppressed guinea pigs.
    Litwińska B; Abramow-Newerly W; Sadowski W; Kańtoch M
    Acta Microbiol Pol; 1984; 33(1):37-40. PubMed ID: 6205547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of antigenicity of inactivated measles vaccine on guinea pigs.
    Drevo M; Mares I; Závadová H
    J Hyg Epidemiol Microbiol Immunol; 1968; 12(4):389-96. PubMed ID: 5752126
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.